Adalimumab: A fully human monoclonal anti-tumor necrosis factor-alpha antibody

Formulary

Volumn 38, Issue 5, 2003, Pages 272-289

  Edwards, Lisa A ^a  

^a Advanced Pharmacy Concepts   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CENTOCOR; ETANERCEPT; IMMUNEX; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; APPENDICITIS; BLEEDING; CANCER; DRUG APPROVAL; DRUG EFFICACY; EDEMA; ERYTHEMA; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HEADACHE; HERPES ZOSTER; HUMAN; INFECTION; INJECTION PAIN; JOINT INJURY; NAUSEA; NEUROLOGIC DISEASE; PAIN; PROSPECTIVE PRICING; PRURITUS; QUALITY OF LIFE; RASH; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

EID: 0037880424     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. CDC: Prevalence of self-reported arthritis or chronic joint symptoms among adults - United States, 2001. MMWR 2002;51:948-50.
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46(2):328-46.
3. MacLean CH, Louie R, Leake B, et al. Quality of care for patients with rheumatoid arthritis. JAMA 2000;284(8):984-92.
4. Pisetsky DS, St. Clair EW. Progress in the treatment of rheumatoid arthritis. JAMA 2001;286:2787-90.
5. Koopman WJ. Prospects for autoimmune disease. JAMA 2001;285:648-50.
6. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. NEJM 2001;344:907-16.
7. Emery P. The new science of rheumatoid arthritis treatment. Medscape Program. Available at: www.medscape.com/viewprogram/628_pnt. Accessed July 2, 2002.
8. Rau R. Adalimumab (a fully human anti-tumour necrosis factor-α monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 2002;61 (Suppl II):ii70-3.
9. Kineret (anakinra) [package insert]. Thousand Oaks, Calif: Amgen; October 2002.
10. Enbrel (etanercept) [package insert]. Seattle, Wash: Immunex Corp; October 2002.
11. Remicade (infliximab) [package insert]. Malvern, Pa: Centocor Inc; June 2002.
12. den Broeder A, van de Putte LB, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-α antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002;29:2288-98.
13. Correspondence from Abbott Laboratories. Professional information and product safety. Abbott Park, Ill. November 12, 2002.
14. Editors for The Pink Sheet. Issue: October 14, 2002:27.
15. Press release: Abbott Laboratories seeks US and European regulatory approvals for rheumatoid arthritis treatment D2E7 (Adalimumab). Abbott Park, Ill. April 9, 2002.
16. Press release: Abbott Laboratories receives FDA approval earlier than anticipated for Humira™(adalimumab) for the treatment of RA. Abbott Park, Ill. December 31, 2002. Available at: www.abbott.com/news/press_release.cfm? id=524. Accessed January 2, 2003.
17. Press release: Abbott Laboratories announces unprecedented drug access program for new rheumatoid arthritis drug Humira™(adalimumab), for Medicare-eligible seniors. Abbott Park, Ill. Available at: www.abbott.com/news/press_release. cfm?id=527. Accessed January 7, 2003.
18. Editors for The Pink Sheet. Issue: January 6, 2003:3-4.
19. Humira™(adalimumab) [package insert]. North Chicago, Ill: Abbott Laboratories; December 2002.
20. Kempeni J. Update on D2E7: a fully human antitumour necrosis factor-α monoclonal antibody. Ann Rheum Dis 2000;59(suppl I):i44-5.
21. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor-α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA Trial. Arthritis & Rheum 2003;48:35-45.
22. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNF-α monoclonal antibody D2E7. Ann Rheum Dis 1999;58(Suppl I):170-2.
23. Kavanaugh A, Weinblatt M, Keystone E, et al. The ARMADA Trial: 12-month efficacy and safety of combination therapy with adalimumab (D2E7), the first fully human anti-TNF monoclonal antibody, and methotrexate (MTX) in patients with active rheumatoid arthritis. Abstract presented at: The European Congress of Rheumatology, June 12-15, 2002, Stockholm, Sweden.
24. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab (D2E7), the first fully human anti-TNF monoclonal antibody, in patients with rheumatoid arthritis who Failed previous DMARD therapy: 6-month results from a phase 3 study. Program #467. Abstract presented at: The European Congress of Rheumatology, June 12-15, 2002, Stockholm, Sweden.
25. Keystone E, Kavanaugh AF, Sharp J, et al. Adalimumab (D2E7), A fully human anti-TNF-α monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy. Program #468. Abstract presented at: The 66th Annual Meeting of the American College of Rheumatology, October 24-29, 2002, New Orleans, La.
26. Furst DE, Fleischmann R, Birbara C, et al. Efficacy of adalimumab (D2E7), the first fully human anti-TNF monoclonal antibody, administered to rheumatoid arthritis patients in combination with other antirheumatic therapy in the STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis) Trial. Abstract presented at: The European Congress of Rheumatology, June 1215, 2002, Stockholm, Sweden.
27. Burmester GR, van de Putte LB, Rau R, et al. 2-Year experience with adalimumab (D2E7), the first fully human anti-TNF monoclonal antibody, in patients with DMARD-refractory rheumatoid arthritis. Abstract presented at: The European Congress of Rheumatology, June 12-15, 2002, Stockholm, Sweden.
28. Press release: First phase 3 data for Abbott Laboratories' D2E7 (adalimumab) support promise in rheumatoid arthritis (RA): Results presented at European rheumatology meeting suggest safety and durability of response in RA. The European Congress of Rheumatology, June 14, 2002, Stockholm, Sweden.
29. Schiff M, Furst D, Strand V, et al. A randomized controlled safety trial of adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, given to RA patients in combination with standard rheumatologic care: STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Program #1537. Abstract presented at: The European Congress of Rheumatology, June 14, 2002, Stockholm, Sweden.
30. FDA Advisory Committee. Arthritis committee will reconsider TNF inhibitor safety March 4. Available at: www.fdaadvisorycommittee.com. Accessed January 29, 2003.
31. FDA Advisory Committee. TNF inhibitor labeling on risk of lymphoma should caution against comparisons between agents. Available at: www.fdaadvisorycommittee.com. Accessed April 22, 2003.